Seek Returns

LLY vs. ORCL: Eli Lilly vs. Oracle Stock Comparison

How do Eli Lilly (LLY) and Oracle (ORCL) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Oracle (ORCL) belongs to Information Technology (Software & Services) — their GICS classifications point to very different parts of the market.

Company profile comparison for Eli Lilly (LLY) and Oracle (ORCL)
Profile ItemLLYORCL
NameEli Lilly and CompanyOracle Corporation
Country/RegionUnited StatesUnited States
GICS SectorHealth CareInformation Technology
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesSoftware & Services
GICS IndustryPharmaceuticalsSoftware
GICS Sub-IndustryPharmaceuticalsSystems Software
Market Capitalization1,206.07 billion USD361.97 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateJune 1, 1972March 12, 1986
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

LLY
ORCL
GSPC
Loading price history…
Eli Lilly (LLY) vs. Oracle (ORCL), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Eli Lilly (LLY) and Oracle (ORCL). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Eli Lilly (LLY) and Oracle (ORCL). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Eli Lilly (LLY) and Oracle (ORCL)
MetricLLYORCL
Total Return (1Y)52.36%-49.72%
Total Return (3Y, Annualized)34.18%3.11%
Total Return (5Y, Annualized)41.08%6.07%

Risk Profile

Drawdown History

LLY
ORCL
GSPC
Loading price history…
Eli Lilly (LLY) vs. Oracle (ORCL), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Eli Lilly (LLY) and Oracle (ORCL). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Oracle (ORCL) has an aggressive beta of 1.80, indicating higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.40 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk profile metrics for Eli Lilly (LLY) and Oracle (ORCL)
MetricLLYORCL
Volatility (1Y, Annualized)35.34%59.45%
Beta (5Y)0.401.80
Max Drawdown (5Y)-34.48%-64.58%
Avg. Volume (3M)2.52M33.24M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
LLY and ORCL are plotted by 1-year volatility (risk) and 1-year return. Each dashed Capital Allocation Line uses that stock's own industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Eli Lilly (LLY) and Oracle (ORCL)
MetricLLYORCL
Sharpe Ratio (1Y)1.36-0.91
Sortino Ratio (1Y)2.29-1.29

Profitability

ROE (TTM)

Both Eli Lilly (LLY) at 86.02% and Oracle (ORCL) at 41.19% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max
109.18%
LLY
86.02%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ORCL

Software & Services industry group

41.19%

Max
53.85%
ORCL
41.19%
Q3
17.90%
Median
6.59%
Q1
-9.59%
Min
-50.52%
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their ROE against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

Net Margin (TTM)

Eli Lilly (LLY) at 31.90% keeps the most of each sales dollar — above its industry’s net margin range — and Oracle (ORCL) at 26.36% also retains a top-quartile share.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY
31.90%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ORCL

Software & Services industry group

26.36%

Max
41.17%
ORCL
26.36%
Q3
15.28%
Median
4.63%
Q1
-5.42%
Min
-33.17%
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their net margin against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

Operating Margin (TTM)

Both Eli Lilly (LLY) at 53.66% and Oracle (ORCL) at 35.63% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max
83.12%
LLY
53.66%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ORCL

Software & Services industry group

35.63%

Max
46.89%
ORCL
35.63%
Q3
17.64%
Median
8.73%
Q1
-2.13%
Min
-30.45%
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their operating margin against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

Profitability Metrics

Profitability metrics for Eli Lilly (LLY) and Oracle (ORCL)
MetricLLYORCL
ROE (TTM)86.02%41.19%
ROA (TTM)21.06%6.36%
Net Margin (TTM)31.90%26.36%
Operating Margin (TTM)53.66%35.63%
Gross Margin (TTM)83.63%63.96%

Growth

Revenue Growth

Both Eli Lilly (LLY) at 44.70% and Oracle (ORCL) at 17.35% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their Revenue Growth across different time periods.

EPS Growth

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Oracle (ORCL) at 34.33% is closer to the peer norm — faster per-share earnings growth for LLY.

Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Eli Lilly (LLY) and Oracle (ORCL)
MetricLLYORCL
Revenue Growth (YoY)44.70%17.35%
Revenue Growth (3Y CAGR)31.69%10.48%
EPS Growth (YoY)95.99%34.33%
EPS Growth (3Y CAGR)51.71%23.84%

Financial Strength

Current Ratio (MRQ)

Oracle (ORCL) at 1.17 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
LLY
1.39
Min
0.10

ORCL

Software & Services industry group

1.17

Max
5.11
Q3
2.77
Median
1.67
ORCL
1.17
Q1
1.01
Min
0.03
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their current ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

Debt / Equity (MRQ)

Both Eli Lilly (LLY) at 1.23 and Oracle (ORCL) at 2.52 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max
1.42
LLY
1.23
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

ORCL

Software & Services industry group

2.52

ORCL
2.52
Max
2.52
Q3
1.13
Median
0.40
Q1
0.07
Min
0.00
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their debt-to-equity ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

Financial Strength Metrics

Financial strength metrics for Eli Lilly (LLY) and Oracle (ORCL)
MetricLLYORCL
Current Ratio (MRQ)1.391.17
Debt / Equity (MRQ)1.232.52
Net Debt / EBITDA0.963.84

Dividends

Dividend Yield (TTM)

Both Eli Lilly (LLY) at 0.49% and Oracle (ORCL) at 1.74% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY
0.49%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ORCL

Software & Services industry group

1.74%

ORCL
1.74%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their dividend yield against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

Dividend Payout Ratio (TTM)

Both Eli Lilly (LLY) at 21.71% and Oracle (ORCL) at 31.35% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY
21.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ORCL

Software & Services industry group

31.35%

ORCL
31.35%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their payout ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

Dividend Metrics

Dividend metrics for Eli Lilly (LLY) and Oracle (ORCL)
MetricLLYORCL
Dividend Yield (TTM)0.49%1.74%
Dividend Payout Ratio (TTM)21.71%31.35%

Valuation

P/E Ratio (TTM)

Oracle (ORCL) at 18.20 sits in the cheaper P/E ratio quartile, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max
85.34
LLY
43.95
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

ORCL

Software & Services industry group

18.20

Max
112.94
Q3
60.32
Median
32.91
Q1
18.77
ORCL
18.20
Min
6.69
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their P/E ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

P/S Ratio (TTM)

On P/S ratio, both Eli Lilly (LLY) at 13.95 and Oracle (ORCL) at 5.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max
58.18
Q3
25.77
LLY
13.95
Median
7.30
Q1
3.01
Min
0.01

ORCL

Software & Services industry group

5.04

Max
17.91
Q3
8.78
ORCL
5.04
Median
4.25
Q1
2.23
Min
0.02
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their P/S ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

P/B Ratio (MRQ)

Oracle (ORCL) at 5.68 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY
29.96
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

ORCL

Software & Services industry group

5.68

Max
16.63
Q3
8.50
ORCL
5.68
Median
4.30
Q1
1.92
Min
-3.90
Loading chart…
Eli Lilly (LLY) vs. Oracle (ORCL): A comparison of their P/B ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Software & Services industry group benchmarks.

Valuation Metrics

Valuation metrics for Eli Lilly (LLY) and Oracle (ORCL)
MetricLLYORCL
P/E Ratio (TTM)43.9518.20
P/S Ratio (TTM)13.955.04
P/B Ratio (MRQ)29.965.68
Free Cash Flow Yield (TTM)0.77%-12.67%